[{"id":"a9a958a0-54fc-401f-80e7-fc0331ae93eb","acronym":"MyDRUG","url":"https://clinicaltrials.gov/study/NCT03732703","created_at":"2021-01-18T18:17:27.493Z","updated_at":"2025-02-25T13:18:42.828Z","phase":"Phase 1/2","brief_title":"Myeloma-Developing Regimens Using Genomics (MyDRUG)","source_id_and_acronym":"NCT03732703 - MyDRUG","lead_sponsor":"Multiple Myeloma Research Consortium","biomarkers":" BRAF • SLC1A5","pipe":"","alterations":" ","tags":["BRAF • SLC1A5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Cotellic (cobimetinib) • Verzenio (abemaciclib) • Balversa (erdafitinib) • Xpovio (selinexor) • Ninlaro (ixazomib) • Darzalex (daratumumab) • dexamethasone • Idhifa (enasidenib) • pomalidomide • Blenrep (belantamab mafodotin-blmf) • GDC-0623"],"overall_status":"Completed","enrollment":" Enrollment 103","initiation":"Initiation: 04/01/2019","start_date":" 04/01/2019","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2025-02-14"},{"id":"1ff726df-4ae8-4795-97b5-a7e91fde5bce","acronym":"","url":"https://clinicaltrials.gov/study/NCT05208307","created_at":"2022-01-26T12:53:35.060Z","updated_at":"2025-02-25T13:12:53.198Z","phase":"Phase 2","brief_title":"Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma","source_id_and_acronym":"NCT05208307","lead_sponsor":"Emory University","biomarkers":" CD4","pipe":" | ","alterations":" Chr t(4;14) • Chr t(14;16)","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(4;14) • Chr t(14;16)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pomalidomide • Blenrep (belantamab mafodotin-blmf) • Hemady (dexamethasone tablets)"],"overall_status":"Recruiting","enrollment":" Enrollment 34","initiation":"Initiation: 07/21/2022","start_date":" 07/21/2022","primary_txt":" Primary completion: 10/21/2025","primary_completion_date":" 10/21/2025","study_txt":" Completion: 10/21/2026","study_completion_date":" 10/21/2026","last_update_posted":"2024-08-12"},{"id":"9dcb826a-6f40-4c36-9dae-a741f622b8ee","acronym":"DREAMM-3","url":"https://clinicaltrials.gov/study/NCT04162210","created_at":"2021-01-18T20:17:55.897Z","updated_at":"2024-07-02T16:34:36.734Z","phase":"Phase 3","brief_title":"Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)","source_id_and_acronym":"NCT04162210 - DREAMM-3","lead_sponsor":"GlaxoSmithKline","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dexamethasone • pomalidomide • Blenrep (belantamab mafodotin-blmf)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 325","initiation":"Initiation: 04/02/2020","start_date":" 04/02/2020","primary_txt":" Primary completion: 09/12/2022","primary_completion_date":" 09/12/2022","study_txt":" Completion: 06/26/2025","study_completion_date":" 06/26/2025","last_update_posted":"2024-06-10"},{"id":"515a5a14-9b53-4739-889a-3f02b77c0eee","acronym":"","url":"https://clinicaltrials.gov/study/NCT05065047","created_at":"2021-10-01T11:54:39.857Z","updated_at":"2024-07-02T16:35:05.067Z","phase":"Phase 1","brief_title":"Belantamab Mafadotin Maintenance Therapy After Salvage Autologous Hematopoietic Cell Transplantation in Patients With Relapse Refractory Multiple Myeloma","source_id_and_acronym":"NCT05065047","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Blenrep (belantamab mafodotin-blmf)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 01/05/2023","start_date":" 01/05/2023","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 05/01/2025","study_completion_date":" 05/01/2025","last_update_posted":"2024-05-08"},{"id":"d24f8d9a-9e2f-4861-9181-2b0a6f6b5ba4","acronym":"","url":"https://clinicaltrials.gov/study/NCT05556798","created_at":"2022-09-27T14:04:44.698Z","updated_at":"2024-07-02T16:35:05.385Z","phase":"Phase 1","brief_title":"A Study of Belantamab Mafodotin in Combination With Nirogacestat and Pomalidomide in People With Multiple Myeloma That Has Not Responded to Treatment or Has Come Back After Treatment","source_id_and_acronym":"NCT05556798","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" SDC1","pipe":"","alterations":" ","tags":["SDC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pomalidomide • Blenrep (belantamab mafodotin-blmf) • Ogsiveo (nirogacestat)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 10/04/2022","start_date":" 10/04/2022","primary_txt":" Primary completion: 10/01/2026","primary_completion_date":" 10/01/2026","study_txt":" Completion: 10/01/2026","study_completion_date":" 10/01/2026","last_update_posted":"2024-05-07"},{"id":"ad746174-b4d7-4aaa-814e-ece7ffe13d48","acronym":"COSTA","url":"https://clinicaltrials.gov/study/NCT05874193","created_at":"2023-05-24T18:06:41.191Z","updated_at":"2024-07-02T16:35:08.416Z","phase":"Phase 2","brief_title":"A Collaborative Community Effort Using Belantamab Mafodotin in Relapsed/Refractory Myeloma","source_id_and_acronym":"NCT05874193 - COSTA","lead_sponsor":"Cristiana Costa Chase, DO","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Blenrep (belantamab mafodotin-blmf)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 33","initiation":"Initiation: 06/01/2024","start_date":" 06/01/2024","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 09/01/2027","study_completion_date":" 09/01/2027","last_update_posted":"2024-04-22"},{"id":"8c189e73-7839-42ec-89f2-d58afc05f72f","acronym":"","url":"https://clinicaltrials.gov/study/NCT04177823","created_at":"2021-01-18T20:22:29.877Z","updated_at":"2024-07-02T16:35:08.515Z","phase":"Phase 1","brief_title":"A Study of Belantamab Mafodotin to Investigate Safety, Tolerability, Pharmacokinetics, Immunogenicity and Clinical Activity in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)","source_id_and_acronym":"NCT04177823","lead_sponsor":"GlaxoSmithKline","biomarkers":" CD8","pipe":" | ","alterations":" CD38 positive","tags":["CD8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD38 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Blenrep (belantamab mafodotin-blmf)"],"overall_status":"Completed","enrollment":" Enrollment 6","initiation":"Initiation: 12/09/2019","start_date":" 12/09/2019","primary_txt":" Primary completion: 12/30/2022","primary_completion_date":" 12/30/2022","study_txt":" Completion: 12/30/2022","study_completion_date":" 12/30/2022","last_update_posted":"2024-04-19"},{"id":"fd9ebc09-6d35-46a3-abd9-f9c124160735","acronym":"EAE120","url":"https://clinicaltrials.gov/study/NCT05280275","created_at":"2022-03-15T18:52:55.764Z","updated_at":"2025-02-25T13:12:55.381Z","phase":"Phase 1/2","brief_title":"A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Transplant Ineligible","source_id_and_acronym":"NCT05280275 - EAE120","lead_sponsor":"Hellenic Society of Hematology","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • Darzalex (daratumumab) • dexamethasone • Blenrep (belantamab mafodotin-blmf)"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 04/13/2022","start_date":" 04/13/2022","primary_txt":" Primary completion: 03/15/2026","primary_completion_date":" 03/15/2026","study_txt":" Completion: 03/15/2026","study_completion_date":" 03/15/2026","last_update_posted":"2023-12-01"},{"id":"2edaec8d-eed2-4793-8244-dd50e749a2b4","acronym":"","url":"https://clinicaltrials.gov/study/NCT05573802","created_at":"2022-10-10T14:05:36.991Z","updated_at":"2025-02-25T13:13:10.445Z","phase":"Phase 1/2","brief_title":"A Study to Investigate Safety and Clinical Activity of Belantamab Mafodotin in Combination With Lenalidomide, Dexamethasone and Nirogacestat in Patients With Transplant Ineligible Newly Diagnosed Multiple Myeloma","source_id_and_acronym":"NCT05573802","lead_sponsor":"Hellenic Society of Hematology","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • dexamethasone • Blenrep (belantamab mafodotin-blmf) • Ogsiveo (nirogacestat)"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 07/14/2023","start_date":" 07/14/2023","primary_txt":" Primary completion: 10/31/2026","primary_completion_date":" 10/31/2026","study_txt":" Completion: 10/31/2026","study_completion_date":" 10/31/2026","last_update_posted":"2023-10-24"},{"id":"6a2118f7-f4ed-47ee-b68b-d30be8e0cf00","acronym":"BelaRd","url":"https://clinicaltrials.gov/study/NCT04808037","created_at":"2021-03-19T15:59:18.313Z","updated_at":"2025-02-25T13:20:01.120Z","phase":"Phase 1/2","brief_title":"Blmf, Lenalidomide and Dexamethasone in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma","source_id_and_acronym":"NCT04808037 - BelaRd","lead_sponsor":"Hellenic Society of Hematology","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • dexamethasone • Blenrep (belantamab mafodotin-blmf) • dexamethasone injection"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 66","initiation":"Initiation: 02/22/2021","start_date":" 02/22/2021","primary_txt":" Primary completion: 09/08/2028","primary_completion_date":" 09/08/2028","study_txt":" Completion: 11/08/2028","study_completion_date":" 11/08/2028","last_update_posted":"2023-10-24"},{"id":"af618ed1-f3a8-4f1c-b68f-d34b62bb09f6","acronym":"","url":"https://clinicaltrials.gov/study/NCT05581875","created_at":"2022-10-17T14:56:46.978Z","updated_at":"2025-02-25T13:13:10.924Z","phase":"Phase 1/2","brief_title":"A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Pomalidomide and Dexamethasone in Patients With Relapsed/ Refractory Multiple Myeloma Previously Treated With One Line Therapy Who Are Lenalidomide Refractory","source_id_and_acronym":"NCT05581875","lead_sponsor":"Hellenic Society of Hematology","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • Darzalex (daratumumab) • dexamethasone • pomalidomide • Blenrep (belantamab mafodotin-blmf)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 10/20/2022","start_date":" 10/20/2022","primary_txt":" Primary completion: 10/31/2026","primary_completion_date":" 10/31/2026","study_txt":" Completion: 10/31/2026","study_completion_date":" 10/31/2026","last_update_posted":"2022-10-17"},{"id":"19519372-1a62-41b5-8333-b1b11738ce08","acronym":"GEM-BELA-VRd","url":"https://clinicaltrials.gov/study/NCT04802356","created_at":"2021-03-17T15:57:36.680Z","updated_at":"2025-02-25T13:19:59.235Z","phase":"Phase 2","brief_title":"Belantamab Mafodotin in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients","source_id_and_acronym":"NCT04802356 - GEM-BELA-VRd","lead_sponsor":"PETHEMA Foundation","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • bortezomib • dexamethasone • melphalan • Blenrep (belantamab mafodotin-blmf)"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 04/07/2021","start_date":" 04/07/2021","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2021-12-06"}]